Kevin Conlon MD

Associate Professor in Medicine, InternalMedicine, Rush University Medical Center

Building 10 CRC Room 5A22 National Cancer InstituteNational Institute of Health 9000 Rockville Pike Bethesda MDBethesda, MD 20892
Phone+1 301-402-2913
Fax+1 301-402-1001

Dr. Conlon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Conlon's full profile Already have an account?

Education & Training

Rush University Medical CenterResidency, Internal Medicine, 1983 - 1987
Rush Medical College of Rush University Medical CenterClass of 1983

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 1987 - 2026
IL State Medical License 1983 - 2014
American Board of Internal Medicine Internal Medicine

Clinical Trials

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
COMPLETED
PHASE2
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Start of enrollment: 1997 Jun 07
COMPLETED
Roles: Contact, Principal Investigator
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Start of enrollment: 2022 Nov 03
WITHDRAWN
PHASE1
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

1 citations
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
Max J Gordon, Milos D Miljkovic, Paige Milhon, Rahul Lakhotia, Christopher Melani
Blood Advances. 2026-05-26
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.
Junya Tabata, Tzu-Ting Huang, Elena Giudice, Kristen R Ibanez, Jayakumar R Nair
Nature Communications. 2026-03-16
3 citations
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.
Max J Gordon, Sigrid Dubois, Milos D Miljkovic, Samuel Ng, Bonita Bryant
Blood Neoplasia. 2025-02-01

Journal Articles

IL-2 and IL-15 Blockade by BNZ-1, an Inhibitor of Selective Γ-chain Cytokines, Decreases Leukemic T-cell Viability
Kevin C Conlon, Thomas A Waldmann, Nature

Abstracts/Posters

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies
Kevin C Conlon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia
Kevin C Conlon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019